Vaccines for the prevention of neglected diseases - Dengue fever

Current Opinion in Biotechnology

Volumn 14, Issue 3, 2003, Pages 332-336

  Pang, Tikki ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; DENGUE VACCINE; DNA VACCINE; LIVE VACCINE; VIRUS VECTOR;

CELLULAR IMMUNITY; CLINICAL TRIAL; COMMUNITY; DENGUE; DENGUE VIRUS; DRUG SAFETY; ENVELOPE GENE; EXPERIMENTAL MODEL; FLAVIVIRUS; HEALTH EDUCATION; HUMAN; IMMUNOPATHOGENESIS; LICENSING; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; VACCINE PRODUCTION;

DENGUE VIRUS; FLAVIVIRUS; RNA VIRUSES;

EID: 0037805585     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(03)00061-2     Document Type: Review

References (31)

1. State of the World's Vaccines and Immunization. Geneva: World Health Organization; 2002.
2. Gubler D.J. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol. 10:2002;100-103.
3. Gibbons R.V., Vaughn D.W. Dengue: an escalating problem. BMJ. 324:2002;1563-1566.
4. Clarke T. Break-bone fever. Nature. 416:2002;672-674.
5. Guzman M.G., Kouri G. Dengue: an update. Lancet Inf. Dis. 2:2002;33-42 Elegant, comprehensive and contemporary review of all the key issues by a group with very extensive actual experience of DF and DHF outbreaks over a period of more than 40 years.
6. Halstead S.B., Deen J. The future of dengue vaccines. Lancet. 360:2002;1243-1245.
7. Almond J., Clemens J., Engers H., Halstead S., Khiem H.B., Pablos-Mendez A., Pervikov Y., Tram T.T. Accelerating the development and introduction of a dengue vaccine for poor children, 5-8 December 2001, Ho Chi Minh City, VietNam. Vaccine. 20:2002;3043-3046.
8. Kanesa-thasan N., Sun W., Kim-Ahn G., van Albert S., Putnak J.R., King A., Raengsakulsrach B., Christ-Schmidt H., Gilson K., Zahradnik J.M. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine. 19:2001;3179-3188.
9. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., Sirivichayakul C., Pengsaa K., Pojjaroen-Anant C., Cholejindachai W.et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio and multiple doses. Am. J. Trop. Med. Hyg. 66:2002;264-272.
10. Edelman R, Wasserman SS, Bodison SA: Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 2003: in press.
11. Monath T.P., McCarthy K., Bedford P., Johnson C.T., Nichols R., Yoksan S., Marchesani R., Knauber M., Wells K.H., Arroyo J.et al. Clinical proof of principle for Chimerivax™: recombinant, live, attenuated vaccines against flavivirus infections. Vaccine. 20:2002;1004-1018 Milestone publication demonstrating the potential for chimeric vaccines against dengue infections utilising the yellow fever vaccine backbone. Added advantage of only requiring a single dose.
12. Johnson B.W., Chambers T.V., Crabtree M.B., Bhatt T.R., Guirakhoo F., Monath T.P., Miller B.R. Growth characteristics of Chimerivax-DEN 2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes. Am. J. Trop. Med. Hyg. 67:2002;260-265.
13. Kenney R.M., Huang C.Y.H. Development of new vaccines against dengue fever and Japanese encephalitis. Intervirology. 44:2001;176-197.
14. Markoff L., Pang X., Houng H.S., Falgout B., Olsen R., Jones E., Polo S. Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys. J. Virol. 76:2002;3318-3328.
15. Durbin A.P., Karron R.A., Sun W., Vaughn D.W., Reynolds M.J., Perrault J.R., Thumar B., Men R., Lai C.J., Elkins W.R.et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am. J. Trop. Med. Hyg. 65:2001;405-413.
16. Troyer J.M., Hanley K.A., Whitehead S.S., Strickman D., Karron R.A., Durbin A.P., Murphy B.R. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. Am. J. Trop. Med. Hyg. 65:2001;414-419.
17. Pletnev A.G., Putnak R.B., Speicher J., Wagar E.J., Vaughn D.W. West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc. Natl. Acad Sci. USA. 99:2002;3036-3041.
18. Raviprakash K., Marques E., Ewing D., Lu Y., Phillips I., Porter K.R., Kochel T.J., August T.J., Hayes C.G., Murphy G.S. Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF. Virology. 260:2001;74-82.
19. Simmons M., Murphy G.S., Kochel T., Raviprakash K., Hayes C.G. Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine. Am. J. Trop. Med. Hyg. 65:2001;420-426.
20. Vàsquez S., Guzman M.G., Guillen G., Chinea G., Pérez A.B., Pupo M., Rodriguez R., Reyes O., Garray E.H., Delgado I.et al. Immune response to synthetic peptides of dengue prM protein. Vaccine. 20:2002;1823-1830.
21. Konishi E., Fujii A. Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine. Vaccine. 20:2002;1058-1067.
22. Guzman M.G., Kouri G., Valdes L., Bravo J., Vàzquez S., Halstead S.B. Enhanced severity of secondary dengue-2 infections; death rates in 1981 and 1997 Cuban outbreaks. Pan. Am. J. Publ. Hlth. 11:2002;223-227 Powerful illustration of the importance and longevity of the immune enhancement phenomenon in the causation of DHF and the crucial need for vaccine candidates to induce long-term protective immunity against all four dengue serotypes.
23. Kochel T.J., Watts D.M., Halstead S.B., Hayes C.G., Espinoza A., Felices V., Caceda R., Bautista C.T., Montoya Y., Douglas S.et al. Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue hemorrhagic fever. Lancet. 360:2002;310-312 Important report suggesting that the pathogenicity of dengue viruses is influenced by its genotype; the Southeast Asian genotype of DEN-2 causes DHF/DSS whereas the American genotype causes the milder DF.
24. Endy T.P., Nisalak A., Chunsuttiwat S., Libraty D., Green S., Rothman A.L., Vaughn D.W., Ennis F.A. Spatial and temporal circulation of dengue virus serotypes: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am. J. Epidemiol. 156:2002;52-59 Excellent example of a population-based, prospective cohort study. More studies of this type will be needed in endemic areas to better understand the links between disease severity, serological responses and dengue virus serotypes.
25. Mangada M.M., Endy T.P., Nisalak A., Chunsuttiwat S., Vaughn D.W., Libraty D.H., Green S., Ennis F.A., Rothman A.L. Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren. J. Infect. Dis. 185:2002;1697-1703.
26. Guidelines for the Evaluation of Dengue Vaccines in Populations Exposed to Natural Infection: Geneva: TDR/IVR, World Health Organization; 2002.
27. Kay B.H., Nam V.S., Tien T.V., Yen N.T., Phong T.V., Diep V.T., Ninh T.U., Bektas A., Aaskov J.G. Control of aedes vectors of dengue in three provinces of Vietnam by use of Mesocyclops (Copepoda) and community-based methods validated by entomologic, clinical, and serological surveillance. Am. J. Trop. Med. Hyg. 66:2002;40-48.
28. Chambers T.J., Liang Y., Droll D.A., Schlesinger J.J., Davidson A.D., Wright P.J., Jiang X. Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model. J. Virol. 77:2003;3655-3668.
29. Whitehead S.S., Falgout B., Hanley K.A., Blaney J.E. Jr., Markoff L., Murphy B.R. A live attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ untranslated region is highly attenuated and immunogenic in monkeys. J. Virol. 77:2003;1653-1657.
30. Cologna R., Rico-Hesse R. American genotype structures decrease dengue virus output from human monocytes and dendritic cells. J. Virol. 77:2003;3929-3938.
31. Nisalak A., Endy T.P., Nimmanitya S., Kalayanrooj S., Thisyakorn U., Scott R.M., Burke D.S., Hoke C.H., Innis B.L., Vaughn D.W. Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. Am. J. Trop. Med. Hyg. 68:2003;191-202.